Statements of Stockholders' Equity - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Service Receivable	Accumulated Deficit
Balance (in shares) at Dec. 31, 2017		60,600	733,217
Balance at Dec. 31, 2017	$ 6,506,107	$ 60	$ 5,279	$ 179,546,954	$ 0	$ (173,046,186)
Increase (Decrease) in Stockholders' Equity
Sale of common stock and warrants, net of expenses (in shares)			1,523,333
Sale of common stock and warrants, net of expenses	11,779,525		$ 914	11,778,611
Sale of stock, net of expenses (in shares)		8,860
Sale of Series B Convertible Preferred Stock, net of expenses	4,386,762	$ 9		4,386,753
Stock-based compensation	2,174,627			2,174,627
Issuance of common stock upon exercise of warrants (in shares)			78,917
Issuance of common stock upon exercise of warrants	1,612,667		$ 569	1,612,098
Issuance of common stock upon vesting of restricted stock awards (in shares)			18,609
Issuance of common stock upon vesting of restricted stock awards	0		$ 94	(94)
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance	0			2,769,533		(2,769,533)
Issuance of common stock upon conversion of Series B Convertible Preferred Stock (in shares)		(8,860)	1,476,667
Issuance of common stock upon conversion of Convertible Preferred Stock	0	$ (9)	$ 886	(877)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(24,240)					(24,240)
Issuance of common stock for share rounding as a result of reverse stock split (in shares)			1,136
Cumulative effect of change in accounting principle related to revenue recognition	109,922					109,922
Net loss	(16,461,178)					(16,461,178)
Balance (in shares) at Dec. 31, 2018		60,600	3,831,879
Balance at Dec. 31, 2018	10,084,192	$ 60	$ 7,742	202,267,605	0	(192,191,215)
Increase (Decrease) in Stockholders' Equity
Sale of common stock and warrants, net of expenses (in shares)			1,994,929
Sale of common stock and warrants, net of expenses	$ 8,817,772		$ 199	8,817,573
Sale of stock, net of expenses (in shares)	1,994,929		4,761,754
Stock-based compensation	$ 884,942			884,942
Issuance of common stock upon exercise of warrants (in shares)			2,221,635
Issuance of common stock upon exercise of warrants	3,299,510		$ 223	3,299,287
Issuance of common stock upon vesting of restricted stock awards (in shares)			22,057
Issuance of common stock upon vesting of restricted stock awards	0		$ 5	(5)
Issuance of common stock upon conversion of Series B Convertible Preferred Stock (in shares)		(200,000)	333,333
Issuance of common stock upon conversion of Convertible Preferred Stock	0	$ (200)	$ 33	167
Preferred stock dividend payable on Series A Convertible Preferred Stock	(24,240)					(24,240)
Issuance of common stock for share rounding as a result of reverse stock split (in shares)			6,466
Net loss	(16,414,159)					(16,414,159)
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (in shares)		200,000	183,334
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount	(40,000)	$ 200	$ 110	1,634,690	(1,675,000)
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance	0			268,269		(268,269)
Release of clinical trial funding commitment	703,327				703,327
Balance (in shares) at Dec. 31, 2019		60,600	8,593,633
Balance at Dec. 31, 2019	$ 7,311,344	$ 60	$ 8,312	$ 217,172,528	$ (971,673)	$ (208,897,883)